US Edition
Three-Year Data Reveals Long-Term Power of Bimekizumab for PsA
Summary by dermatologytimes.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
All
Left
Center
Right
Three-Year Data Reinforce Bimzelx® as a Durable Option for Chronic Inflammatory Arthritis
At the first day of the European Alliance of Associations for Rheumatology (EULAR) 2025 meeting, UCB presented three‑year, phase III plus open‑label extension data for Bimzelx® (bimekizumab‑bkzx), a dual IL‑17A/F inhibitor for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). In PsA cohorts—including biologic DMARD‑naïve and TNFi‑inadequate‑response patients—nearly 60% achieved complete resolution of swollen joints (SJC=0), and over…
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium